Efficacy and Safety of 80-mg Osimertinib in Patients With Leptomeningeal Metastases Associated With EGFR-Mutated NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Phase II Efficacy and Safety of 80 mg Osimertinib in Patients With Leptomeningeal Metastases Associated With Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer (BLOSSOM)
J. Clin. Oncol 2024 Jun 03;[EPub Ahead of Print], S Park, R Baldry, HA Jung, JM Sun, SH Lee, JS Ahn, YJ Kim, Y Lee, DW Kim, SW Kim, KH Lee, WJ Lee, JW Choi, K Chong, JI Lee, SH Gwon, NH Son, MJ AhnFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.